Conatus Pharmaceuticals (CNAT) Misses Q4 EPS by 9c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $800 million versus the consensus estimate of $1.67 million.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49